First Test for All Known Human Coronaviruses, Including SARS-CoV-2 Variants


Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health and SunYat-Sen University in China have set the stage for the development of highly sensitive antibody tests for infection with all known human coronaviruses, including new variants of SARS-CoV-2. The research is published in Communications Biology, a Nature journal.

The HCoV-Peptide array developed by CII scientists consists of 3 million immune markers on a glass chip, covering proteins of all known human coronaviruses, including the SARS-CoV-2. In collaboration with a team at Sun Yat-Sen University, the CII researchers identified 29 immune signatures specific to SARS-CoV-2. These genetic fingerprints (peptides) provide the blueprint for tests that will be used for diagnostics and surveillance. Current antibody tests for SARS-CoV-2 infection may generate false-positive results because of cross-reactivity with seasonal coronaviruses responsible for the common cold, as well as MERS-CoV and SARS-CoV-1.

To develop the HCoV-Peptide array, the researchers first analyzed blood samples taken from individuals with asymptomatic, mild, or severe SARS-CoV-2 infections, and controls including healthy individuals and those exposed to SARS-CoV-1 and seasonal coronaviruses. An analysis of all approximately 170,000 peptides related to known human coronaviruses yielded 29 peptides with the strongest and most specific reactivity with SARS-CoV-2. Next, they validated their test using a second set of blood samples, including those from confirmed cases of SARS-CoV-2, those with antibodies to other human coronaviruses, and healthy individuals.

The new test has a 98 percent specificity and sensitivity. Immune signatures were present from eight days after onset of COVID-19 symptoms to as long as six to seven months after infection.

“This work will allow us and others to build inexpensive, easy-to-use blood tests that can provide data for exposure as well as immunity,” says author Nischay Mishra, PhD, assistant professor of epidemiology at the Columbia Mailman School.

“This work with our colleagues at SunYat-Sen, led by Professor Jiahai Lu, and with Nimble Therapeutics, underscores the importance to public health of global collaboration and partnerships with industry in addressing the challenges of the COVID-19 pandemic,” says senior and corresponding author W. Ian Lipkin, MD, director of CII and John Snow Professor of Epidemiology.

Previously, the researchers have used similar methods to develop tests for Zika, acute flaccid myelitis, and tick-borne infections.

Co-authors also include Shreyas Joshi, Cheng Guo, James Ng, Riddhi Thakkar, Adrian Caciula, Rafal Tokarz, and Thomas Briese at CII; Xi Huang, Yongjian Wu, Xin Dong, Qianlin Li, and Jiahai Lu at Sun Yat-sen University, Guangzhou, China; and Richard Pinapati and Eric Sullivan at Nimble Therapeutics Inc, Madison, WI. Nischay Mishra, W. Ian Lipkin, Rafal Tokarz, Shreyas Joshi, Cheng Guo, and Thomas Briese are listed as the inventors on a patent filed that is related to findings in this study.

Research at Columbia was supported by the Chau Hoi Shuen Foundation and the Marin Community Foundation. Work at Sun Yat-Sen was funded by the Guangdong Scientific and Technological Research for COVID-19 (202020012612200001) and the National Science and Technology Major Project (No. 2018ZX10101002-001-001). • Contributed

Find your latest news here at the Hemet & San Jacinto Chronicle


Please enter your comment!
Please enter your name here

Share post:

Subscribe to The Hemet & San Jacinto Chronicle


More like this

Judge rules Donald Trump defrauded banks, insurers as he built real estate empire

A judge has ruled that Donald Trump committed fraud for years while building the real estate empire that catapulted him to fame and the White House.

California governor signs law raising taxes on guns and ammunition to pay for school safety

California will double the taxes on guns and ammunition and use the money to pay for more security at public schools and various violence prevention programs under a new law Gov. Gavin Newsom signed Tuesday.

CMS Statement on Current Status of Blood Tests for Organ Transplant Rejection

The Centers for Medicare & Medicaid Services (CMS) confirms that neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients’ ability to have blood tests used to monitor for organ transplantation rejection covered when ordered by their physicians in medically appropriate circumstances.

The Health Divide: Is the media reporting on the booster rollout in communities of color?

As the COVID numbers continue to climb across the country, journalists should be paying close attention to how the latest information on infections and vaccines is perceived in communities of color. And if you don’t yet have sources in these communities, listening to the radio or print outlets serving these audiences is one of the best tools.